AptarGroup has appointed Gael Touya as president and chief executive officer, effective 1 September 2026, succeeding Stephan Tanda, who has led the company since 2017 and will retire by the end of the year.
Touya, who has spent more than 30 years at the company, most recently served as president of Aptar Pharma, where he oversaw approximately 82% topline growth since 2018. During that period he expanded the segment's technology and services portfolio, extended respiratory and nasal drug delivery into systemic applications, and advanced nasal delivery technologies into biologics.
Candace Matthews, chairperson of AptarGroup, said the board had unanimously concluded Touya was the best candidate following a process that considered both internal and external candidates.
Tanda's tenure saw adjusted EBITDA margins expand from approximately 19% to 22%, adjusted earnings per share grow 67%, and capital returned to shareholders increase by around 100%. The company also marked its 32nd consecutive year of paying an annually increasing dividend in 2025.
Tanda will continue in an advisory capacity through the end of 2026 to support the transition before retiring from the board.
AptarGroup is a global supplier of drug delivery, dosing, protection, and consumer dispensing technologies, listed on the New York Stock Exchange.
